Evidence map›Paper›PMID 33212015›Full record

ArticleCell systems2020

The Most Logical Approach to Improve CAR T Cell Therapy.

Seunghee Lee, Wilson W Wong

Abstract readComment
PubMed Publisher
In one paragraph

Article in Cell systems, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Seunghee LeeDepartment of Biomedical Engineering, and Biological Design Center, Boston University, Boston, MA, USA.
Wilson W WongDepartment of Biomedical Engineering, and Biological Design Center, Boston University, Boston, MA, USA. Electronic address: wilwong@bu.edu.

Funding

Synthetic toolkit for precision gene expression control and signal processing in mammalian cellsR01EB029483 · NIBIB · HARVARD UNIVERSITY · PI Ahmad Samir Khalil · 2020 to 2026
$5.0M
Synthetically Reengineered T cells as the Next Generation of Smart Cancer TherapyDP2CA186574 · NCI · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI WONG, WILSON · 2013 to 2013
$2.5M
Advanced recombinase-based gene expression technology in mammalian cellsR01GM129011 · NIGMS · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI WONG, WILSON · 2019 to 2022
$1.5M
Engineering a smart CAR platform for human regulatory T cellsR56EB027729 · NIBIB · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI DOOMS, HANS PETER, EMILI, ANDREW · 2019 to 2019
$357k
NCI NIH HHS DP2 CA186574NIBIB NIH HHS R01 EB029483NIBIB NIH HHS R56 EB027729NIGMS NIH HHS R01 GM129011
6 · The paper itself

Abstract

Combinational antigen recognition is the most logical way to improve the safety of cancer therapy. CAR T cells therapy, combined with synthetic biology, protein engineering, and bioinformatics, can perform advanced computations to enhance tumor targeting specificity.

Indexed as

NeoplasmsReceptors, Chimeric AntigenHumansImmunotherapy, AdoptiveT-LymphocytesReceptors, Chimeric Antigen

Identifiers

PMID33212015

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.